Abdul Rahman Jazieh, Chief Executive Officer at Innovative Healthcare Institute, shared a post on LinkedIn:
“It is well known that certain medications alter the efficacy of immunotherapy in solid tumors. The concerns started with steroid for obvious reason then antibiotics emerged as a detrimental factor.
But more commonly used medications such as acetaminophen or PPIs make the issue more pressing if we need to optimize the patient care and attain the best outcome. (See attached JCO article!).
Therefore, it is critical to review the indications of every medication the patient is taking and discontinue those with no strong indications.
The second issue is to ask specifically about the supplements that patients ingest, which are often ignored or overlooked and deal with them as medications.”
Title: Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors
Authors: Nicholas DeVito, Erica Gray, Daniel Schrum, Scott Antonia
Read the Full Article.
Other articles featuring Abdul Rahman Jazieh on OncoDaily.